User profiles for Sherika Hanley
 | Sherika HanleyFamily medicine specialist and clinical trials investigator - University of KwaZulu-Natal … Verified email at ukzn.ac.za Cited by 997 |
[HTML][HTML] Efficacy of NVX-CoV2373 Covid-19 vaccine against the B. 1.351 variant
Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) …
variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) …
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir …
Background Antiretroviral therapy (ART) during pregnancy is important for both maternal
health and prevention of perinatal HIV-1 transmission; however adequate data on the safety …
health and prevention of perinatal HIV-1 transmission; however adequate data on the safety …
[HTML][HTML] Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised …
Background There is a paucity of data on COVID-19 vaccines in people living with HIV-1,
who could be at increased risk of severe illness and death from COVID-19. We evaluated the …
who could be at increased risk of severe illness and death from COVID-19. We evaluated the …
[HTML][HTML] Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an …
Background Safe and potent antiretroviral medications in child-friendly formulations are
needed to treat young children living with HIV-1. We aimed to select dosing for a dispersible …
needed to treat young children living with HIV-1. We aimed to select dosing for a dispersible …
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase …
…, J de Jager, M Rossouw, L Rossouw, S Hanley… - The Lancet …, 2023 - thelancet.com
Background Drugs taken during pregnancy can affect maternal and child health outcomes,
but few studies have compared the safety and virological efficacy of different antiretroviral …
but few studies have compared the safety and virological efficacy of different antiretroviral …
[HTML][HTML] Obesity in young South African women living with HIV: A cross-sectional analysis of risk factors for cardiovascular disease
Background Young South African women are faced with a dual epidemic of HIV and obesity,
placing them at a high risk of developing atherosclerotic cardiovascular disease (CVD). We …
placing them at a high risk of developing atherosclerotic cardiovascular disease (CVD). We …
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT …
Background Long-acting injectable cabotegravir and rilpivirine have demonstrated safety,
acceptability, and efficacy in adults living with HIV-1. The IMPAACT 2017 study (MOCHA study…
acceptability, and efficacy in adults living with HIV-1. The IMPAACT 2017 study (MOCHA study…
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV …
…, I Deprez, AC Desmond, K Han, S Hanley… - The Lancet …, 2024 - thelancet.com
Background Combined intramuscular long-acting cabotegravir and long-acting rilpivirine
constitute the first long-acting combination antiretroviral therapy (ART) regimen approved for …
constitute the first long-acting combination antiretroviral therapy (ART) regimen approved for …
Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir-and Tenofovir Alafenamide Fumarate–Containing Antiretroviral Treatment Regimens During …
…, F Nakayiwa, V Ndyanabangi, S Hanley… - Clinical Infectious …, 2024 - academic.oup.com
Background We evaluated associations between antepartum weight change and adverse
pregnancy outcomes and between antiretroviral therapy (ART) regimens and week 50 …
pregnancy outcomes and between antiretroviral therapy (ART) regimens and week 50 …
[HTML][HTML] The multi-country PROMOTE HIV antiretroviral treatment observational cohort in Sub-Saharan Africa: Objectives, design, and baseline findings
…, B Makanani, L Chinula, MM Nyati, S Hanley… - PloS one, 2018 - journals.plos.org
Background The PROMOTE study aims to measure long-term antiretroviral treatment (ART)
safety and adherence; compare HIV disease progression; assess subsequent adverse …
safety and adherence; compare HIV disease progression; assess subsequent adverse …